Study guide
24.2 Version History, Resolution Evidence and Noncompliance
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
24.2 Version History, Resolution Evidence and Noncompliance
Key Takeaways Explain This Topic AI
Superseded versions and actual dates support reconstruction of conduct.
A promise or closed tracker status alone does not prove a finding was resolved.
Significant noncompliance requires appropriate action and evaluated follow-up.
Last updated: October 2026
Version History, Resolution Evidence and Noncompliance
Under ICH E6(R3), essential documents must be filed in a timely and contemporaneous manner. Delayed filing—a systemic pathology known in clinical operations as "filing debt" —represents a severe regulatory vulnerability.
The Doctrine of Inspection Readiness
"Inspection readiness" requires that the Trial Master File and Investigator Site File be maintained in a continuous state of completeness, currency, and accuracy, such that an auditor or regulatory inspector could inspect the files at any given moment and reconstruct the conduct of the trial without supplemental verbal explanations.
Critical Filing Pitfalls & Pathologies
Post-Dating and Back-Dating (Fraudulent Practice): Site personnel or monitors must NEVER back-date a signature, document, or log entry to make it appear timely. Back-dating constitutes intentional fraud. If a document is executed or filed late, it must be signed with the actual current calendar date , accompanied by a clear, contemporaneous note explaining the delay (e.g., "Late entry: Form completed on 18-Oct-2026 reflecting training conducted on 12-Oct-2026." ).
Orphaned Documents: Documents filed without required parent context (e.g., an IRB approval letter filed without the corresponding protocol amendment version, or a CV filed without a medical license).
Superseded Document Governance: When new protocol versions or revised consent forms are approved, the previous versions must not be discarded or destroyed. The superseded version must remain filed in the binder, clearly stamped or marked as "SUPERSEDED" with the effective date, to preserve the historical audit trail.
Electronic repository controls
Electronic essential records need suitable access controls, traceable changes, version history and reliable retrieval throughout the retention period. Sponsor and site responsibilities should remain clear when a service provider hosts the repository. Confirm how site records will be retained when a sponsor portal closes; a bookmark to an expiring service is not an archive.
A certified copy permanently replacing an original should preserve the same information, including relevant context, content and structure. Verify migrations rather than assuming a visible PDF contains every attachment, metadata field or electronic signature. Control the change and confirm readability with the people responsible for future access.
Distinguishing reports, communications and resolution evidence
A monitoring report can record that a missing consent page was identified, while a follow-up letter assigns the site an action. Neither alone proves that the page was located or that the participant-rights issue was evaluated. Reconciliation should follow the issue through the site's response, relevant evidence and sponsor review. If the page cannot be recovered, retain an honest limitation and the evaluated action rather than creating a replacement signature page.
A completed action tracker can refer to evidence held elsewhere. Verify the reference works and the responsible parties can retrieve the record. An email attachment that exists only in a departed employee's personal mailbox is a retention risk. An electronic repository can be appropriate if the content, metadata, access and ownership remain controlled.
Also distinguish a confirmed correction from a promise. A site response saying training will be completed next week is not evidence that staff were trained before already performed activities. Maintain the dates and prospective plan without rewriting the earlier gap. A useful record permits reconstruction of both the problem and the response, including remaining uncertainty and its impact.
The same principle applies to a sponsor-only monitoring report. The site need not hold every internal report, but it needs appropriate communication of findings affecting its responsibilities and records of its own response. File ownership and participant protection should both be clear rather than solved by indiscriminate copying.
Managing Serious Non-Compliance, Audits/Inspections & Site Close-Out (COV)
Note
Clinical trial operations culminate in three rigorous evaluative gateways: resolving persistent or serious site non-compliance, withstanding independent quality audits and regulatory inspections, and conducting comprehensive site close-out. Under ICH E6(R3), sponsors must take prompt action when an investigator or institution fails to comply with the protocol, GCP, or regulatory requirements. Concurrently, sponsors and investigators must maintain continuous readiness for independent audits and regulatory inspections under the applicable framework before bringing the trial to an orderly close under ICH E6(R3).
The final stages of a clinical trial test the robustness of a site's operational integrity. Whether managing critical protocol non-compliance, hosting federal regulatory inspectors, or executing the detailed multi-domain checklist of a Site Close-Out Visit (COV), the Clinical Research Associate serves as the critical operational anchor ensuring compliance, audit defensibility, and long-term inspection readiness.
Managing Serious and Persistent Site Non-Compliance (ICH E6(R3))
Non-compliance occurs whenever an investigator, site staff member, sponsor representative, or third-party vendor fails to adhere to the approved clinical protocol, standard operating procedures (SOPs), Good Clinical Practice principles, or applicable statutory regulations.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 .